Retatrutide Side Effects Observed in Clinical Trials
Documented adverse event data from Phase 2 and Phase 3 Retatrutide clinical trials — frequencies, severity distributions, serious risk signals, and what the class-effect literature says about discontinuation. All figures refer to enrolled trial participants only.
Common Retatrutide Side Effects
Retatrutide side effects in Phase 2 and Phase 3 clinical trials are predominantly gastrointestinal, dose-dependent, and most prominent during the dose-escalation period. The following frequencies are drawn from Phase 2 obesity trial data (n=338, up to 48 weeks, 12 mg maximum dose).[3]
Phase 2 (n=338, 48 weeks) and Phase 3 TRIUMPH-1 (n=2,339, 80 weeks). Frequencies are for the 12 mg arm in each trial. GI adverse events were predominantly mild to moderate.[3][23]
| Adverse event | Phase 2, 12 mg | Phase 3, 12 mg | Severity |
|---|---|---|---|
| Nausea | ~60% | 42.4% | Predominantly mild to moderate; peak in escalation weeks |
| Diarrhea | 15–33% | 32.0% | Dose-dependent range |
| Vomiting | 21–26% | 25.3% | Mild to moderate; higher-dose arms |
| Constipation | 11–16% | 26.1% | Dose-dependent |
| Decreased appetite | ~14% | N/R | As an adverse event, distinct from intended effect |
| Injection-site reactions | ~8% | N/R | Across all active arms |
No deaths were reported in either Phase 2 trial. No pancreatitis or thyroid C-cell tumor signals were identified in Phase 3 data to date.[23] The safety profile was described as consistent with incretin-based therapy class.
Serious Risks Studied in Retatrutide Trials
Serious adverse events were uncommon in Phase 2 and Phase 3 Retatrutide data. The following signals were monitored or observed.[3][16][23]
Retatrutide increased heart rate by up to 6.7 beats per minute in Phase 2 obesity trial data. The increase peaked at approximately week 24 and declined thereafter. This glucagon-receptor-mediated chronotropic effect is a monitored safety signal across the ongoing TRIUMPH trials. Systolic blood pressure decreased in Phase 2 data, partially offsetting the chronotropic concern.[16]
One participant in the Phase 2 type 2 diabetes cohort (8 mg arm, n=26) experienced atrial fibrillation (3.85%).[16] This is a single event in a small cohort; clinical significance at the program level is under evaluation.
Pancreatitis: A theoretical class-effect risk based on GLP-1 receptor agonism; no pancreatitis signal was identified in Phase 3 data to date.[23]
Thyroid C-cell risk: Preclinical observations with GLP-1R agonism in rodents; no signal identified in Retatrutide Phase 3 data to date.[23]
Glucagon agonism in T2D: The GCGR component raises theoretical concern for hepatic glycogenolysis and elevated blood glucose in fasting states. Net glycemic effect across trials is favorable because GLP-1R and GIPR co-activation counterbalances the glycogenolytic effect. Phase 2 type 2 diabetes data showed significant HbA1c improvement.[4]
The cardiovascular outcomes trial TRIUMPH-OUTCOMES (NCT06383390) is the registrational safety study. Long-term cardiovascular outcomes data from the full TRIUMPH program are pending.
What Happens When You Stop Retatrutide?
No Retatrutide-specific long-term discontinuation study has been published as of mid-2026. The class-effect pattern observed with analogous compounds provides the current best inference.[19]
Weight regain after stopping GLP/GIP-class agonists is well-documented in published RCT data. STEP 4 (semaglutide withdrawal study) documented 6.9% weight regain after switching to placebo versus continued −7.9% loss. SURMOUNT-4 (tirzepatide withdrawal) documented 14.0% regain after switching versus continued −5.5% loss.[19]
The metabolic mechanism is counterregulatory: after stopping appetite-suppressing treatment, orexigenic signaling recovers, metabolic rate may adapt downward, and caloric intake tends to return toward pre-treatment levels. Most lost weight has been recovered within 12 months in the analogous-compound withdrawal studies.[19]
Retatrutide-specific discontinuation data are expected from longer-term follow-up in the TRIUMPH program. Until those data are published, the class-effect pattern represents the available inference.
Weight Regain After Discontinuing Retatrutide
Weight regain on discontinuation of GLP/GIP-class agonists follows a consistent pattern in the published discontinuation literature: the majority of lost weight is recovered within 12 months of stopping treatment.[19] This pattern has been documented in semaglutide STEP 4 and tirzepatide SURMOUNT-4 discontinuation data.[19]
The underlying biology is treatment-dependent appetite suppression: once GIPR and GLP-1R agonism is removed, hypothalamic orexigenic signaling and caloric intake return toward pre-treatment baselines. The drug was suppressing the drive to eat; removing it does not confer lasting behavioral change in most participants.
The one notable potential exception in Retatrutide’s data is the preclinical oncology model: anti-tumor immune reprogramming persisted after drug withdrawal despite weight regain — suggesting that at least some immunological effects may outlast treatment.[8] Whether any metabolic changes show similar durability in humans is not known from published data.
For Phase 2 and Phase 3 trial results showing the weight trajectories during active treatment, see the research page.